Evaluation of the safety and feasibility of rapid rituximab infusion.

Aim: To assess safety of rapid infusion by measuring infusion-related side effects and toxicities.

Methods: Participants received the first rituximab infusion according to the manufacturers' recommendations. If well-tolerated, they then received the second and subsequent infusions at a rate of 20% of the dose over the first 30 min and the remaining 80% over the next hour.